Unit
Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems (U900)
Thematic areas of research:
Image
To top
Unit
EMMANUEL BARILLOT
Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems (U900)
Our Unit studies several aspects of cancer pathology and treatments, focusing on the underlying molecular and cellular mechanisms: initiation (estimation of cancer risks, including genetic and non-genetic factors, optimisation of patient follow-up strategies)
Teams
Key figures
80
publications in 2020
24
PhD Students in 2020
4
chairs at Institut PRAIRIE
Key publications
All publications
-
-
-
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort studyAmerican Journal of Obstetrics and Gynecology
-
Multiethnic genome‐wide association study of differentiated thyroid cancer in the EPITHYR consortiumInternational Journal of Cancer
-
-
Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survivalInternational Journal of Cancer
News
All news
-
The PR[AI]RIE institute, specializing in AI, obtains an endowment of €75 million and becomes PR[AI]RIE-PSAIIn 2019, Institut Curie participated in the creation of PR[AI]RIE, one of the four French artificial intelligence (AI) institutes born as part of the national initiative on AI announced by President Emmanuel Macron. The goal ? Revolutionize interdisciplinary research, training, and innovation in AI. Five years later, PR[AI]RIE, which is now among the world leaders in the sector, becomes PR[AI]RIE-PSAI (Paris School of AI) with a new endowment of €75 million from the AI Cluster program of the France 2030 plan and an emphasized approach to education and training.26/07/2024
-
100% digital pathology at Institut CurieAll slides from tumor biopsies taken from new patients treated at Institut Curie are now digitized thanks to the work of the team at the Diagnostic and Theranostic Medicine Division (PMDT) at the Hospital Group.03/04/2023
-
Suggérer des traitements potentiels du cancer de la prostate grâce à des modèles mathématiquesDes chercheurs de l'Institut Curie et de l'Université de Heidelberg ont évalué une approche mathématique afin de développer des modèles (ou patients virtuels) permettant d’évaluer les traitements personnalisés les plus efficaces pour des patients atteints de cancer de la prostate.18/02/2022
Scientific events
All scientific events
4 Sep
2024
Seminar
14h-15h
Generative AI for acceleration of drug discovery
...
15 Mar
2024
Seminar
16h-18h
Slide-tags enables single-nucleus barcoding for multimodal spatial genomics
For this session, we will host Jackson A. Weir who works in Fei Chen lab at the Broad Institute. Recent technological innovations have enabled the high-throughput quantification of gene expression and epigenetic regulation within individual cells, transforming our understanding of how complex tissues are constructed. However, missing from these measurements is the ability to routinely and easily s
8 Dec
2023
Seminar
12h-13h
"Paired multiplex imaging and spatial transcriptomics to decipher the tumor cells-fibroblasts crosstalk in lung and head & neck cancer "
Already the 10th seminar of the series ! For this session, we will host Helene Salmon , head of the Stroma and Immunity lab in Curie (U932). She will present their insights in paired multiplex imaging and spatial transcriptomics to decipher the tumor cells-fibroblasts crosstalk in lung and head & neck cancer.
Do not forget! The scope of this seminar is to share how people working
Do not forget! The scope of this seminar is to share how people working
13 Sep
2023
Seminar
14h-15h
The visualisation of genomic data using the UCSC genome browser
...
22 May
2023
In house seminar
12h-13h
Next generation molecular tumor boards: systems biology and functional precision medicine
Clinical oncology, computer science, and molecular biology are today united at the molecular tumor boards that provide clinical decision support to physicians and patients. I will present some learnings from the first two years of a nation-wide molecular tumor board in Norway, and how this is aligned with the research strategy in my group where we study systems biology approaches to predict drug r